Related Experiment Video
Updated: Jan 3, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia
Zhiheng Cheng1,2,3,4, Yifeng Dai2, Yifan Pang5
1Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Abstract:
The mammalian target of rapamycin (mTOR) inhibitor, DNA damage inducible transcript 4 (DDIT4), has inducible expression in response to various cellular stresses. In multiple malignancies, studies have shown that DDIT4 participates in tumorigenesis and impacts patient survival. We aimed to study the prognostic value of DDIT4 in acute myeloid leukaemia (AML), which is currently unclear. Firstly, The Cancer Genome Atlas was screened for AML patients with complete clinical characteristics and DDIT4 expression data. A total of 155 patients were included and stratified according to the treatment modality and the median DDIT4 expression levels. High DDIT4 expressers had shorter overall survival (OS) and event-free survival (EFS) than the low expressers among the chemotherapy-only group (all P < .001); EFS and OS were similar in the high and low DDIT4 expressers of the allogeneic haematopoietic stem cell transplantation (allo-HSCT) group. Furthermore, in the DDIT4high group, patients treated with allo-HSCT had longer EFS and OS than those who received chemotherapy alone (all P < .01). In the DDIT4low group, OS and EFS were similar in different treatment groups. Secondly, we analysed two other cytogenetically normal AML (CN-AML) cohorts derived from the Gene Expression Omnibus database, which confirmed that high DDIT4 expression was associated with poorer survival. Gene Ontology (GO) enrichment analysis showed that the genes related to DDIT4 expression were mainly concentrated in the acute and chronic myeloid leukaemia signalling pathways. Collectively, our study indicates that high DDIT4 expression may serve as a poor prognostic factor for AML, but its prognostic effects could be outweighed by allo-HSCT.
Insights
High DNA damage inducible transcript 4 (DDIT4) expression indicates a poor prognosis in acute myeloid leukaemia (AML), particularly with chemotherapy. However, allogeneic stem cell transplantation may overcome this negative impact.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- DNA damage inducible transcript 4 (DDIT4), an inhibitor of the mammalian target of rapamycin (mTOR), is induced by cellular stress.
- DDIT4 plays a role in tumorigenesis and affects patient survival in various cancers.
- The prognostic significance of DDIT4 in acute myeloid leukaemia (AML) remains largely unelucidated.
Purpose of the Study:
- To investigate the prognostic value of DDIT4 expression in patients with acute myeloid leukaemia (AML).
- To determine the impact of DDIT4 levels on survival outcomes in AML based on treatment modality.
Main Methods:
- Analysis of DDIT4 expression and clinical data from 155 AML patients in The Cancer Genome Atlas (TCGA).
- Stratification of patients based on DDIT4 expression levels (high vs. low) and treatment (chemotherapy vs. allogeneic haematopoietic stem cell transplantation [allo-HSCT]).
- Validation in two independent cytogenetically normal AML (CN-AML) cohorts from the Gene Expression Omnibus (GEO) database and Gene Ontology (GO) enrichment analysis.
Main Results:
- In the chemotherapy-only group, high DDIT4 expression was significantly associated with shorter overall survival (OS) and event-free survival (EFS) (P < .001).
- In the allo-HSCT group, no significant difference in OS or EFS was observed between high and low DDIT4 expressers.
- Patients with high DDIT4 expression treated with allo-HSCT showed improved EFS and OS compared to those receiving chemotherapy (P < .01), an effect not seen in the low DDIT4 group. Validation cohorts confirmed high DDIT4 as a marker of poorer survival. GO analysis linked DDIT4 to AML signalling pathways.
Conclusions:
- High DDIT4 expression is a potential poor prognostic factor in acute myeloid leukaemia (AML).
- The negative prognostic impact of high DDIT4 expression may be mitigated or overcome by allogeneic haematopoietic stem cell transplantation (allo-HSCT).
- DDIT4 warrants further investigation as a therapeutic target or biomarker in AML management.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Abnormal Proliferation

